全文获取类型
收费全文 | 12633篇 |
免费 | 935篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 108篇 |
儿科学 | 356篇 |
妇产科学 | 255篇 |
基础医学 | 2092篇 |
口腔科学 | 124篇 |
临床医学 | 1190篇 |
内科学 | 2846篇 |
皮肤病学 | 224篇 |
神经病学 | 1406篇 |
特种医学 | 308篇 |
外科学 | 1367篇 |
综合类 | 53篇 |
一般理论 | 2篇 |
预防医学 | 979篇 |
眼科学 | 234篇 |
药学 | 877篇 |
中国医学 | 28篇 |
肿瘤学 | 1169篇 |
出版年
2023年 | 97篇 |
2022年 | 64篇 |
2021年 | 334篇 |
2020年 | 228篇 |
2019年 | 353篇 |
2018年 | 436篇 |
2017年 | 270篇 |
2016年 | 268篇 |
2015年 | 348篇 |
2014年 | 493篇 |
2013年 | 635篇 |
2012年 | 1072篇 |
2011年 | 1059篇 |
2010年 | 568篇 |
2009年 | 596篇 |
2008年 | 917篇 |
2007年 | 938篇 |
2006年 | 811篇 |
2005年 | 832篇 |
2004年 | 753篇 |
2003年 | 733篇 |
2002年 | 712篇 |
2001年 | 120篇 |
2000年 | 129篇 |
1999年 | 128篇 |
1998年 | 89篇 |
1997年 | 95篇 |
1996年 | 64篇 |
1995年 | 65篇 |
1994年 | 53篇 |
1993年 | 42篇 |
1992年 | 44篇 |
1991年 | 24篇 |
1990年 | 32篇 |
1989年 | 27篇 |
1988年 | 23篇 |
1987年 | 21篇 |
1986年 | 21篇 |
1985年 | 10篇 |
1984年 | 19篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 10篇 |
1978年 | 13篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1974年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 30 毫秒
1.
2.
3.
4.
Isabelle Marie 《Autoimmunity reviews》2019,18(1):62-72
As a mirror image of the Roman god Janus Bifrons, the environment has a hidden face. To highlight this hidden face of the environment in the field of systemic sclerosis (SSc) will allow to identify responsible agents emerging in the future. To date, there is, in fact, a growing scientific evidence that environmental factors have a crucial impact on both alterations and modulation of epigenetic determinants, resulting in SSc onset and progression. It has been well established that there is a marked correlation between SSc onset and occupational exposure to crystalline silica and organic solvents. More recently, an association between SSc and exposure to heavy metals has further been found, including: antimony, cadmium, lead, mercury. These latter findings interestingly underscore that occupational exposure to heavy metals should be systematically checked in all SSc patients at diagnosis, as the identification of the occupational toxic agent will allow its interruption, which may result in potential improvement of SSc outcome. 相似文献
5.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
6.
Shane R. Stecklein Simona F. Shaitelman Gildy V. Babiera Isabelle Bedrosian Dalliah M. Black Matthew T. Ballo Isadora Arzu Eric A. Strom Valerie K. Reed Tomas Dvorak Benjamin D. Smith Wendy A. Woodward Karen E. Hoffman Pamela J. Schlembach Steve M. Kirsner Christopher L. Nelson Jinzhong Yang William Guerra Elizabeth S. Bloom 《Practical radiation oncology》2019,9(1):e4-e13
Purpose
This study aimed to prospectively characterize toxicity and cosmesis after accelerated partial breast irradiation (APBI) with 3-dimensional conformal radiation therapy (CRT) or single-entry, multilumen, intracavitary brachytherapy.Methods and materials
A total of 281 patients with pTis, pT1N0, or pT2N0 (≤3.0 cm) breast cancer treated with segmental mastectomy were prospectively enrolled from December 2008 through August 2014. APBI was delivered using 3-dimensional CRT (n = 29) or with SAVI (n = 176), Contura (n = 56), or MammoSite (n = 20) brachytherapy catheters. Patients were evaluated at protocol-specified intervals, at which time the radiation oncologist scored cosmetic outcome, toxicities, and recurrence status using a standardized template.Results
The median follow-up time is 41 months. Grade 1 seroma and fibrosis were more common with brachytherapy than with 3-dimensional CRT (50.4% vs 3.4% for seroma; P < .0001 and 66.3% vs 44.8% for fibrosis; P = .02), but grade 1 edema was more common with 3-dimensional CRT than with brachytherapy (17.2% vs 5.6%; P = .04). Grade 2 to 3 pain was more common with 3-dimensional CRT (17.2% vs 5.2%; P = .03). Actuarial 5-year rates of fair or poor radiation oncologist-reported cosmetic outcome were 9% for 3-dimensional CRT and 24% for brachytherapy (P = .13). Brachytherapy was significantly associated with inferior cosmesis on mixed model analysis (P = .003). Significant predictors of reduced risk of adverse cosmetic outcome after brachytherapy were D0.1cc (skin) ≤102%, minimum skin distance >5.1 mm, dose homogeneity index >0.54, and volume of nonconformance ≤0.89 cc. The 5-year ipsilateral breast recurrence was 4.3% for brachytherapy and 4.2% for 3-dimensional CRT APBI patients (P = .95).Conclusions
Brachytherapy APBI is associated with higher rates of grade 1 fibrosis and seroma than 3-dimensional CRT but lower rates of grade 1 edema and grade 2 to 3 pain than 3-dimensional CRT. Rates of radiation oncologist-reported fair or poor cosmetic outcomes are higher with brachytherapy. We identified dosimetric parameters that predict reduced risk of adverse cosmetic outcome after brachytherapy-based APBI. Ipsilateral breast recurrence was equivalent for brachytherapy and 3-dimensional CRT. 相似文献7.
8.
Annals of Surgical Oncology - 相似文献
9.